Nicole M Golbari1, Aaron E Katz2. 1. Stony Brook University, Stony Brook, NY, USA. 2. Winthrop University Hospital, Mineola, NY, USA. AKatz@winthrop.org.
Abstract
PURPOSE OF REVIEW: While recurrence after primary treatment of prostate cancer (PCa) is not uncommon, there is currently no consensus on the most appropriate management after radiation treatment failure. This article seeks to explore the currently utilized modalities for salvage treatment for radiorecurrent PCa. We focused our review on the oncologic outcomes and reported toxicity rates in the latest studies examining salvage radical prostatectomy (SRP), salvage cryotherapy (SCT), salvage high-intensity focused ultrasound (HIFU) and re-irradiation. RECENT FINDINGS: There does not appear to be any significant difference in overall survival for more invasive salvage radical prostatectomy compared to the minimally invasive salvage approaches. Additionally, there seems to be a trend towards lower morbidity rates associated with minimally invasive and focal salvage treatment. We are encouraged by the results presented in this review and find that there is clearly a role for emerging minimally invasive and focal therapies as durable options for salvage treatment in patients with radiorecurrent PCa.
PURPOSE OF REVIEW: While recurrence after primary treatment of prostate cancer (PCa) is not uncommon, there is currently no consensus on the most appropriate management after radiation treatment failure. This article seeks to explore the currently utilized modalities for salvage treatment for radiorecurrent PCa. We focused our review on the oncologic outcomes and reported toxicity rates in the latest studies examining salvage radical prostatectomy (SRP), salvage cryotherapy (SCT), salvage high-intensity focused ultrasound (HIFU) and re-irradiation. RECENT FINDINGS: There does not appear to be any significant difference in overall survival for more invasive salvage radical prostatectomy compared to the minimally invasive salvage approaches. Additionally, there seems to be a trend towards lower morbidity rates associated with minimally invasive and focal salvage treatment. We are encouraged by the results presented in this review and find that there is clearly a role for emerging minimally invasive and focal therapies as durable options for salvage treatment in patients with radiorecurrent PCa.
Authors: Niall M Corcoran; Guilherme Godoy; Rodney C Studd; Rowan G Casey; Antonio Hurtado-Coll; Scott Tyldesley; S Larry Goldenberg; Martin E Gleave Journal: Can Urol Assoc J Date: 2013 Mar-Apr Impact factor: 1.862
Authors: Daher C Chade; Shahrokh F Shariat; Angel M Cronin; Caroline J Savage; R Jeffrey Karnes; Michael L Blute; Alberto Briganti; Francesco Montorsi; Henk G van der Poel; Hendrik Van Poppel; Steven Joniau; Guilherme Godoy; Antonio Hurtado-Coll; Martin E Gleave; Marcos Dall'Oglio; Miguel Srougi; Peter T Scardino; James A Eastham Journal: Eur Urol Date: 2011-03-21 Impact factor: 20.096
Authors: Anthony V D'Amico; Richard Whittington; S Bruce Malkowicz; Kerri Cote; Marian Loffredo; Delray Schultz; Ming-Hui Chen; John E Tomaszewski; Andrew A Renshaw; Alan Wein; Jerome P Richie Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Michael J Zelefsky; Michael W Kattan; Paul Fearn; Bertha L Fearon; Jason P Stasi; Alison M Shippy; Peter T Scardino Journal: Urology Date: 2007-08 Impact factor: 2.649
Authors: Andrew Warner; Tom Pickles; Juanita Crook; Andre-Guy Martin; Luis Souhami; Charles Catton; Himu Lukka; George Rodrigues Journal: Cureus Date: 2015-06-11
Authors: Maria Grazia Petrongari; Valeria Landoni; Biancamaria Saracino; Sara Gomellini; Stefano Arcangeli; Giuseppe Iaccarino; Paola Pinnarò; Giorgio Arcangeli; Lidia Strigari Journal: J Exp Clin Cancer Res Date: 2013-12-13
Authors: Wan Song; U Seok Jung; Yoon Seok Suh; Hyun Jun Jang; Hyun Hwan Sung; Hwang Gyun Jeon; Byung Chang Jeong; Seong Il Seo; Seong Soo Jeon; Han Yong Choi; Hyun Moo Lee Journal: Korean J Urol Date: 2014-02-14
Authors: T T Shah; M Peters; A Kanthabalan; N McCartan; Y Fatola; J van der Voort van Zyp; M van Vulpen; A Freeman; C M Moore; M Arya; M Emberton; H U Ahmed Journal: Prostate Cancer Prostatic Dis Date: 2016-07-19 Impact factor: 5.554
Authors: David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall Journal: Lancet Oncol Date: 2016-06-20 Impact factor: 41.316
Authors: Taimur T Shah; Abi Kanthabalan; Marjorie Otieno; Menelaos Pavlou; Rumana Omar; Sola Adeleke; Francesco Giganti; Chris Brew-Graves; Norman R Williams; Jack Grierson; Haroon Miah; Amr Emara; Athar Haroon; Arash Latifoltojar; Harbir Sidhu; Joey Clemente; Alex Freeman; Clement Orczyk; Ashok Nikapota; Tim Dudderidge; Richard G Hindley; Jaspal Virdi; Manit Arya; Heather Payne; Anita Mitra; Jamshed Bomanji; Mathias Winkler; Gail Horan; Caroline M Moore; Mark Emberton; Shonit Punwani; Hashim U Ahmed Journal: Eur Urol Date: 2022-03-31 Impact factor: 24.267
Authors: Brecht Devos; Walid Al Hajj Obeid; Colin Andrianne; Romain Diamand; Alexandre Peltier; Wouter Everaerts; Hein Van Poppel; Roland Van Velthoven; Steven Joniau Journal: World J Urol Date: 2019-01-21 Impact factor: 4.226
Authors: Gregory T Chesnut; Amy L Tin; Arjun Sivaraman; Toshikazu Takeda; Taehyoung Lee; Jonathan Fainberg; Nicole Benfante; Daniel D Sjoberg; Hebert Alberto Vargas; Samson W Fine; Peter T Scardino; James A Eastham; Jonathan A Coleman; Karim A Touijer; Michael J Zelefsky; Behfar Ehdaie Journal: Urol Oncol Date: 2021-02-12 Impact factor: 2.954
Authors: Marieke J Van Son; Max Peters; Marinus A Moerland; Juus L Noteboom; Wietse S Eppinga; Raquel Davila Fajardo; Jan Lagendijk; Jochem R Van der Voort van Zyp Journal: Cureus Date: 2018-04-05